Since KMT2A‐r acute myeloid leukemia (KMT2A‐r‐AML) is characterized by the overexpression of HOXA/MEIS1/PBX3 homeobox genes, tackling the interactions of MEIS1/PBX3 may offer a promising therapeutic approach for treating these AML subtypes [21]. The gene discussed is MEIS1; the disease is acute myeloid leukemia.